Isis Pharmaceuticals Inc (NASDAQ:ISIS)
| 20.81 Data as of May 21 |  +0.35 / +1.71%Today’s Change | 7.56 Today|||52-Week Range 23.03 | +99.33% Year-to-Date |
Latest ISIS News | Press Releases
| Sanofi/REGN Commence Enrollment - Analyst Blog May 15 / Zacks.com | Celgene Attains 52-Week High - Analyst Blog May 14 / Zacks.com |
| Isis Gets $3.5M Milestone Payment - Analyst Blog May 14 / Zacks.com | Isis Reports In-Line Loss - Analyst Blog May 08 / Zacks.com |
Today’s Trading
| Previous close | 20.46 |
| Today’s open | 20.45 |
| Day’s range | -- - -- |
| Volume | 906,524 |
| Average volume (3 months) | 1,616,660 |
| Market cap | $2.3B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | +23.53% |
| Earnings growth (this year) | -17.26% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | +2.99% |
| P/E ratio | NM |
| Price/Sales | 10.29 |
| Price/Book | 11.55 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CRLCharles River Labora... | +0.08 | +0.18% |
| PRXLPAREXEL Internationa... | -0.20 | -0.43% |
| ICLRICON PLC | -0.03 | -0.09% |
| ABCOAdvisory Board Co | +0.80 | +1.59% |
Data as of 4:00pm ET, 05/21/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.23 |
| Annual revenue (last year) | $102.0M |
| Annual profit (last year) | -$65.5M |
| Net profit margin | -64.16% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Stanley T. Crooke, MD, PhD |
Chief Operating Officer, Secretary & Director B. Lynne Parshall, |
Corporate headquarters Carlsbad, California |
Forecasts
